ERAS-801: a selective brain-penetrant EGFR inhibitor with improved activity against EGFR extracellular domain-mutant glioblastoma

被引：0
|
作者：
Nathanson, D. [1 ]
Cadet, D. [2 ]
Okobi, Q. [2 ]
Urner, L. [3 ]
Jung, M. [3 ]
Cloughesy, T. [4 ]
机构：
[1] Univ Calif Los Angeles, Mol & Mol Pharmacol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Chem, Los Angeles, CA USA
[4] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB122
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 19 条
  • [1] ERAS-801 IS A SELECTIVE BRAIN-PENETRANT EGFR INHIBITOR WITH IMPROVED ACTIVITY AGAINST EGFR EXTRACELLULAR DOMAIN-MUTANT GLIOBLASTOMA
    Okobi, Quincy
    Cadet, Dimitri
    Urner, Lorenz
    Jung, Michael
    Cloughesy, Timothy
    Nathanson, David
    NEURO-ONCOLOGY, 2024, 26
  • [2] The CNS-penetrant EGFR inhibitor, ERAS-801, shows promising nonclinical activity in a CNS metastases model of EGFR mutant NSCLC
    Tsang, J.
    Zhao, E.
    Plawat, R.
    Cloughesy, T.
    Nathanson, D.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S32 - S32
  • [3] NX-019, a brain penetrant, mutation selective EGFR inhibitor with broad mutant EGFR activity
    Wilson, K.
    Dusek, R.
    Gammon, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S1588 - S1588
  • [4] A PHASE 1 STUDY OF ERAS-801, A POTENT, SELECTIVE, AND CENTRAL NERVOUS SYSTEM (CNS)-PENETRANT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR, FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
    Wen, Patrick
    Ahluwalia, Manmeet
    Odia, Yazmin
    Mckean, Meredith
    Snyder, James
    Colman, Howard
    Lobbous, Mina
    Nghiemphu, Leia
    Chong, Robert
    Yang, Jennifer
    Patel, Hina
    Vecchio, Daniela
    Lokku, Armend
    Brail, Les
    Mellinghoff, Ingo
    NEURO-ONCOLOGY, 2024, 26
  • [5] Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors
    Tsang, Jonathan E.
    Urner, Lorenz M.
    Kim, Gyudong
    Chow, Kingsley
    Baufeld, Lynn
    Faull, Kym
    Cloughesy, Timothy F.
    Clark, Peter M.
    Jung, Michael E.
    Nathanson, David A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (10): : 1799 - 1809
  • [6] Preclinical Characterization of a Potent, Selective, Brain-Penetrant Inhibitor of Osimertinib-Resistant EGFR Variants
    Amberg-Johnson, K.
    Xu, J.
    Izadi, H.
    Kannan, R.
    Ellery, S.
    Kurhade, S.
    Verras, A.
    Guo, J.
    Jean, B.
    Svensson, M.
    Hsiao, P.
    Evangelista, E.
    Liu, Z.
    Bell, J.
    Futran, A.
    Akinsanya, K.
    Jensen, K. K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S618 - S619
  • [7] Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
    Junttila, M. R.
    Warne, R.
    Repellin, C.
    Sambucetti, L.
    Chang, J.
    Kim, S.
    Kim, H. Y.
    Shin, D. G.
    Park, D. H.
    Patel, R.
    Maneval, E. Chow
    Multani, P. S.
    Daemen, A.
    Friedman, L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [8] Anti-tumor activity of BDTX-1535, an irreversible CNS penetrant inhibitor of multiple EGFR extracellular domain alterations, in preclinical glioblastoma models
    Lucas, M.
    Merchant, M.
    O'Connor, M.
    Smith, S.
    Trombino, A.
    Waters, N.
    Eathiraj, S.
    Ball, J.
    Breschi, A.
    Igartua, K.
    Kang, M.
    Buck, E.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S23 - S23
  • [9] Identification of a novel, brain penetrant, EGFR sparing, ErbB2 inhibitor with activity against oncogenic ErbB2 mutations
    Chicarelli, Mark J.
    Arwood-Levine, Ben
    Bettendorf, Tanna
    Bouhana, Karyn
    Brizendine, Richard
    Cable, LouAnn
    Crow, Michelle
    Fell, Brad
    Fischer, John
    Fulton, Jennifer
    Guarnieri, Anna
    Hillman, Madison
    Jalluri, Ravi
    Krischlunas, Daniel
    Koch, Keith
    Kumar, Vijay
    Malinky, Cori
    Rieger, Rob
    Robinson, John
    Stunkard, Lee
    Sullivan, Francis
    Turton, Roy
    Vine, Logan
    Winski, Shannon
    Zhou, Yeyun
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Identification of a novel EGFR sparing brain penetrant ErbB2 inhibitor with activity against oncogenic ErbB2 mutations
    Chicarelli, Mark J.
    Bouhana, Karyn
    Brizendine, Richard K.
    Cable, LouAnn
    Crow, Michelle
    Fell, Brad
    Fischer, John
    Fulton, Jennifer
    Guarnieri, Anna
    Jalluri, Ravi
    Knox, Hailey
    Koch, Keith A.
    Rieger, Rob
    Robinson, John
    Stunkard, Lee M.
    Sullivan, Francis
    Turton, Roy
    Winski, Shannon
    Zhou, Yeyun
    CANCER RESEARCH, 2023, 83 (07)
12